Invention Grant
- Patent Title: Triazolyl pyrimidinone compounds as PDE2 inhibitors
-
Application No.: US15554614Application Date: 2016-03-11
-
Publication No.: US10358435B2Publication Date: 2019-07-23
- Inventor: Dong-Ming Shen , Christopher J. Sinz , Alejandro Crespo , Johnathan E. Wilson , Troy McCracken , Shimin Xu , Haitang Li
- Applicant: Merck Sharp & Dohme Corp. , Dong-Ming Shen , Christopher J. Sinz , Alejandro Crespo , Johnathan E. Wilson , Troy McCracken , Shimin Xu , Haitang Li
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Sylvia A. Ayler; John C. Todaro
- Priority: WOPCT/CN2015/074396 20150317
- International Application: PCT/US2016/021902 WO 20160311
- International Announcement: WO2016/149058 WO 20160922
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D403/04 ; C07D487/04 ; A61K31/4192 ; A61K31/4196 ; A61K31/506 ; C07D498/04 ; A61P25/00
Abstract:
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Public/Granted literature
- US20180237422A1 TRIAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS Public/Granted day:2018-08-23
Information query
